Cargando…

1941. Coadministration of Bivalent Respiratory Syncytial Virus (RSVpreF) Vaccine With Influenza Vaccine in Older Adults

BACKGROUND: Respiratory syncytial virus (RSV) is an important cause of severe lower respiratory tract illness in older adults. RSV and influenza are both typically seasonal diseases, with peaks during winter in temperate climates. Annual vaccination with high-dose or adjuvanted influenza vaccine for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baber, James A, Quan, Karen, Athan, Eugene, Scott, Robert, Jaques, Anna, Jiang, Qin, Li, Wen, Cooper, David, Cutler, Mark W, Kalinina, Elena, Anderson, Annaliesa S, Swanson, Kena A, Gruber, William C, Gurtman, Alejandra C, Schmoele-Thoma, Beate
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678896/ http://dx.doi.org/10.1093/ofid/ofad500.095

Ejemplares similares

91. Establishing Proof of Concept for a Bivalent RSVpreF Subunit Vaccine for Maternal Immunization
por: Simões, Eric A F, et al.
Publicado: (2022)

Immunogenicity of an AS01-adjuvanted respiratory syncytial virus prefusion F (RSVPreF3) vaccine in animal models
por: Bouzya, Badiaa, et al.
Publicado: (2023)

1942. Potential Public Health Impact of Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Maternal Vaccine for Prevention of RSV among US Infants
por: Hanau, Ahuva, et al.
Publicado: (2023)

Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial
por: Bebia, Zourab, et al.
Publicado: (2023)

1632. Bivalent RSV Prefusion F-Based Subunit Vaccine Generates High Neutralizing Titers in Older Adults
por: Fukushima, Yasushi, et al.
Publicado: (2023)

Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study
por: Shoukat, Affan, et al.
Publicado: (2023)

A Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine With and Without Adjuvant in Healthy Older Adults
por: Baber, James, et al.
Publicado: (2022)

2139. Immunogenicity, reactogenicity and safety of a Respiratory Syncytial Virus prefusion F (RSVPreF3) candidate vaccine co-administered with the seasonal quadrivalent influenza vaccine in older adults
por: Chandler, Reynaldo, et al.
Publicado: (2022)

LB745. Respiratory Syncytial Virus (RSV) Prefusion F Protein Candidate Vaccine (RSVPreF3 OA) is Efficacious in Adults ≥ 60 Years of Age (YOA)
por: Ison, Michael G, et al.
Publicado: (2022)

Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial
por: Leroux-Roels, Isabel, et al.
Publicado: (2022)

121. A Respiratory Syncytial Virus Prefusion F Protein (RSVPreF3) Candidate Vaccine Administered in Older Adults in a Phase I/II Randomized Clinical Trial Is Immunogenic
por: Guiñazú, Javier Ruiz, et al.
Publicado: (2020)

1936. Efficacy of One Dose of the Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Adults ≥ 60 Years of Age Persists for 2 RSV Seasons
por: Ison, Michael G, et al.
Publicado: (2023)

1239. Different Dose Levels of a Respiratory Syncytial Virus Maternal Vaccine Candidate (RSVPreF3) Administered to Non-pregnant Women in a Randomized Clinical Trial Are Immunogenic and Well Tolerated
por: Schwarz, Tino, et al.
Publicado: (2020)

119. A Respiratory Syncytial Virus Prefusion F Protein (RSVPreF3) Candidate Vaccine Administered in Older Adults in a Phase I/II Randomized Clinical Trial Is Well Tolerated
por: Tica, Jelena, et al.
Publicado: (2020)

96. A Candidate Respiratory Syncytial Virus (RSV) Prefusion F Protein Investigational Vaccine (RSVPreF3 OA) Is Immunogenic when Administered in Adults ≥ 60 Years of Age: Results at 6 Months after Vaccination
por: Schwarz, Tino F, et al.
Publicado: (2022)

Phase 1/2 Randomized Study of the Immunogenicity, Safety, and Tolerability of a Respiratory Syncytial Virus Prefusion F Vaccine in Adults With Concomitant Inactivated Influenza Vaccine
por: Falsey, Ann R, et al.
Publicado: (2021)

A Randomized Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine
por: Walsh, Edward E, et al.
Publicado: (2021)

1634. Respiratory Syncytial Virus-Associated Health Care Utilization in the Pivotal Phase 3 Trial RSV Vaccine Efficacy Study In Older Adults Immunized Against RSV Disease (RENOIR)
por: Walsh, Edward E, et al.
Publicado: (2023)

1630. Clinical Profile of Acute Respiratory Illness (ARI) Events in the Phase 3 Trial The RSV Vaccine Efficacy Study iN Older Adults Immunized against RSV Disease (RENOIR)
por: Marc, Gonzalo Pérez, et al.
Publicado: (2023)

Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial
por: Thompson, Allison R., et al.
Publicado: (2018)

Neutralization of BA.4–BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine
por: Zou, Jing, et al.
Publicado: (2023)

Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F Vaccine When Coadministered With a Tetanus, Diphtheria, and Acellular Pertussis Vaccine
por: Peterson, James T, et al.
Publicado: (2021)

2781. Statistical Modeling to Predict Maternal RSV Vaccine Efficacy from Neutralizing Titers
por: Cai, Bing, et al.
Publicado: (2019)

Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults
por: Schmoele-Thoma, Beate, et al.
Publicado: (2019)

Bivalent vaccines effectively protect mice against influenza A and respiratory syncytial viruses
por: Raman, Sathya N. Thulasi, et al.
Publicado: (2023)

Safety of routine childhood vaccine coadministration versus separate vaccination
por: Bauwens, Jorgen, et al.
Publicado: (2022)

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination
por: Bhorat, As’ad E., et al.
Publicado: (2015)

Selection of diverse strains to assess broad coverage of the bivalent FHbp meningococcal B vaccine
por: Harris, Shannon L., et al.
Publicado: (2020)

Immunogenicity and safety of coadministration of COVID-19 and influenza vaccination
por: Wagenhäuser, Isabell, et al.
Publicado: (2023)

Immunogenicity and Reactogenicity of Coadministration of COVID-19 and Influenza Vaccines
por: Gonen, Tal, et al.
Publicado: (2023)

2755. Phase 1/2, First-in-Human Study of the Safety, Tolerability, and Immunogenicity of an RSV Prefusion F-Based Subunit Vaccine Candidate
por: Schmoele-Thoma, Beate, et al.
Publicado: (2019)

Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults
por: Murdoch, Louise, et al.
Publicado: (2023)

Safety, tolerability, and immunogenicity of a novel 4-antigen Staphylococcus aureus vaccine (SA4Ag) in healthy Japanese adults
por: Inoue, Megumi, et al.
Publicado: (2018)

Combination Ad26.RSV.preF/preF protein vaccine induces superior protective immunity compared with individual vaccine components in preclinical models
por: Saeland, Eirikur, et al.
Publicado: (2023)

Vaccine-induced antibody Fc-effector functions in humans immunized with a combination Ad26.RSV.preF/RSV preF protein vaccine
por: Bartsch, Yannic C., et al.
Publicado: (2023)

Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study
por: Sadoff, Jerald, et al.
Publicado: (2021)

Potential impact of the bivalent rLP2086 vaccine on Neisseria meningitidis carriage and invasive serogroup B disease
por: Anderson, Annaliesa S., et al.
Publicado: (2013)

Alcoholism 1941-1951
por: Higgins, John W.
Publicado: (1953)

Diari 1899-1941 /
por: Musil, Robert, 1880-1942
Publicado: (1980)

Persistence of Immune Responses Through 36 Months in Healthy Adults After Vaccination With a Novel Staphylococcus aureus 4-Antigen Vaccine (SA4Ag)
por: Creech, C Buddy, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hcenpkt5kokgl435ofnsvtcv2j